/FW

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Oron YACOBY-ZEEVI et al

Serial No.:

10/645,659

Filed:

August 22, 2003

Group Art Unit: 1644

For:

Heparanase Activity Neutralizing

Anti-Heparanase Monoclonal

Antibody And Other

Anti-Heparanase Antibodies

Attorney

Docket: 26128

Examiner:

DIBRINO, Marianne NMN

8

Exammer.

Mail Stop Missing Parts

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

## RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Dear Sir:

This is a response to the attached Office Communication dated June 18, 2007, which response is being made on or before July 18, 2007, and for which no extension fee is due.

Please find attached a nucleotide and/or amino acid listing in computer readable and paper forms.

## Statement

The content of the paper and computer readable form are the same and include no new matter.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Date: July 16, 2007







COPY

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

JB

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/645,659	08/22/2003	Oron Yacoby-Zeevi	26128	8084	
7590 06/18/2007 Martin D. Moynihan			EXAMINER		
PRTSI, Inc.			DIBRINO, MARIANNE NMN		
P. O. Box 16446 Arlington, VA 22215		•	ART UNIT	PAPER NUMBER	
3			1644		
			MAIL DATE	DELIVERY MODE	
			06/18/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Seq. list. = one month





## UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR I PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
10645659	8/22/03	YACOBY-ZEEVI ET AL.	26128  EXAMINER  DiBrino Marianne	
A				
Martin D. Moynihan PRTSI, Inc.				
P. O. Box 16446 Arlington, VA 22215			ART UNIT	PAPER
			1644	20070604

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner for Patents** 

Please find below a communication from the EXAMINER in charge of this application

This application fails to comply with 37 C.F.R. 1.821-1.825 for the reason(s) listed on the Notice to comply with the sequence rules. The applicants are required to either submit a new CRF and Sequence Listing or a letter authorizing the use of the sequence listing filed with the prior application, along with a statement that the sequences in the two cases are identical.

37 C.F.R. 1.821 (e) A copy of the "Sequence Listing" referred to in paragraph © of this section must also be submitted in computer readable form in accordance with the requirements of § 1.824. The computer readable form is a copy of the "Sequence Listing" and will not necessarily be retained as part of the patent application file. If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified.

(f) In addition to the paper copy required by paragraph © of this section and the computer readable form required by paragraph (e) of this section, a statement that the content of the paper and computer readable copies are the same must be submitted with the computer readable form. Such a statement must be a verified statement if made by a person not registered to practice before the Office.

Any inquiry concerning this communication should be directed to Examiner Marianne DiBrino, Art Unit 1644, whose telephone number is 571-272-0842.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Marianne DiBrino, Ph.D.

Patent Examiner

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

PTO-90C (Rev.04-03)

Application No.: 10/645,659

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth at 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X_1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	5
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	7
X5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	f
7. Other:	
Applicant Must Provide:	
XA substitute computer readable form (CRF) copy of the "Sequence Listing".	
XA substitute paper copy of the "Sequence Listing", as well as an amendment directing its entrinto the specification.	<b>y</b>
XA statement that the content of the paper and computer readable copies are the same and, whapplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b 1.825(d).	
For questions regarding compliance to these requirements, please contact:  For Rules Interpretation, call (703) 308-4216  For CRF Submission Help, call (703) 308-421  Patentln Software Program Support (SIRA)  Technical Assistance	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

m. Dim